
浏览全部资源
扫码关注微信
1.北京中医药大学 北京中医药研究院,国家中医药管理局名医名方重点研究室,北京 100029;
2.国家药品监督管理局 药品审评中心,北京 100022
王停,博士,教授,从事中药新药研发工作,E-mail:wangting1973@sina.com
收稿日期:2019-02-13,
网络出版日期:2019-04-03,
纸质出版日期:2019-07-20
移动端阅览
王停, 林红梅, 周刚, 等. 基于名老中医经验方的中药新药研发策略分析[J]. 中国实验方剂学杂志, 2019,25(14):1-5.
Ting WANG, Hong-mei LIN, Gang ZHOU, et al. Research and Development of New Traditional Chinese Medicine Based on Experienced Prescriptions of Prestigious Chinese Physicians[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(14): 1-5.
王停, 林红梅, 周刚, 等. 基于名老中医经验方的中药新药研发策略分析[J]. 中国实验方剂学杂志, 2019,25(14):1-5. DOI: 10.13422/j.cnki.syfjx.20191420.
Ting WANG, Hong-mei LIN, Gang ZHOU, et al. Research and Development of New Traditional Chinese Medicine Based on Experienced Prescriptions of Prestigious Chinese Physicians[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(14): 1-5. DOI: 10.13422/j.cnki.syfjx.20191420.
名老中医经验方是当代名老中医在临床实践过程中形成的确有疗效的方剂,体现了中医对疾病发生发展规律及核心病机的认识,是组方用药规律的宝贵经验,代表了中医临床最高诊疗水平的治疗方案,是新药研发和科技创新的主要源头。传承名老中医的学术思想和临床经验,挖掘、整理名老中医经验方,开发出中药新药,具有重大的现实意义。基于名老中医经验方的中药新药研发是国家重点鼓励研发的方向,也是目前申报量最大的中药新药类别,但近年来批准上市的此类中药新药却非常少。究其原因,研发人员对国家关于此类中药新药的审评理念及相关技术要求了解不够,导致在中药新药研发策略上存在一定问题,是此类中药新药批准上市数量低的主要原因。为了更好地推进名老中医经验方新药研发工作顺利开展,充分发挥名老中医经验方在中药新药研发中的独特优势,该文针对目前名老中医经验方新药研发中存在的问题,强调以临床价值为导向、重视人用历史、全过程质量控制的中药新药研发理念,并从研发的药学、药效毒理以及临床环节需关注的问题进行了深入地分析和探讨,旨在为广大中药新药研发机构和人员提供借鉴和参考,从而研发出更多满足临床需求的安全、有效、质量可控的中药新药,为实现健康中国战略提供重要保障。
The experienced prescriptions of famous prestigious Chinese physicians are effective prescriptions developed by prestigious Chinese doctors during their long-time clinical practice
which reflect the traditional Chinese medicine (TCM) understanding of the disease development regularity and core pathogenesis. These experienced prescriptions provide valuable experience for medication and prescription regularities
and represent the highest level of TCM treatment and the major sources of new drug research
development and technology innovation. It is of great significance to inherit academic thoughts and clinical experiences of prestigious Chinese physicians
explore and summarize experienced prescriptions
and develop new Chinese drugs. The researches of new drugs based on experienced prescriptions are the major direction encouraged by the government
with the maximum amount of new TCM drug applications but a low approval rate in recent years. The main reason for the low number of approved new TCM drug applications is that researchers know less about evaluation concepts and relevant techniques
leading to problems in research and development strategy. To facilitate a smooth advance of the new drug research and development and take full advantage of the experienced prescriptions
in this paper
we focus on the problems about new drug development of experienced prescriptions
lay emphasis on the new TCM drug research and development concepts of clinical value
history of human application and whole-process quality control
and deeply and systematically analyze concerns in such links as pharmacy
pharmacodynamics
toxicology and clinic application. The purpose of this article is to provide the reference in solving actual problems
the reliable basis of further researches on experienced prescriptions
and the important guarantee for developing more safe
effective and high-quality controllable drugs to meets clinical requirements
so as to achieve the strategy of a healthy China.
国家食品药品监督管理总局 . 2017年度药品审评报告 [EB/OL].( 2018-03-22 ). http://samr.cfda.gov.cn/WS01/CL0844/226865.html .
国家食品药品监督管理总局 . 关注痔血胶囊引起的肝损害 [EB/OL].( 2008-10-28 ). http://samr.cfda.gov.cn/WS01/CL1989/33571.html .
李品 , 王琦 , 彭莉 , 等 . 痔血胶囊水提物和醇提物对大鼠肝毒性的影响 [J]. 中国实验方剂学杂志 , 2017 , 23 ( 8 ): 154 - 159 .
周刚 , 王停 . 关注中药新药研发中潜在的安全性问题 [J]. 中国新药杂志 , 2014 , 23 ( 14 ): 1611 - 1614 .
董玲 , 孙裕 , 裴纹萱 , 等 . 基于全程质量控制理念的中药标准化体系研究思路探讨 [J]. 中国中药杂志 , 2017 , 42 ( 23 ): 4481 - 4487 .
阳长明 . 中药复方新药研究的质量设计、质量完善与技术审评的分阶段要求 [J]. 中草药 , 2017 , 48 ( 16 ): 3253 - 3258 .
王停 , 胡军 , 韩玲 . 骨质疏松症中药新药临床前药效学评价思考 [J]. 中国中药杂志 , 2006 , 31 ( 19 ): 1655 - 1656 .
王停 . 关于中药新药治疗原发性骨质疏松症临床试验关键技术问题的思考 [J]. 中国新药杂志 , 2012 , 21 ( 18 ): 2126-2127,2136 .
王停 , 韩玲 , 朱家谷 , 等 . 中药新药申报资料中长期毒性试验需关注的问题 [J]. 中国新药杂志 , 2012 , 21 ( 13 ): 1457 - 1458 .
国家食品药品监督管理局药品审评中心 . 中药新药用于慢性心力衰竭临床研究技术指导原则 [EB/OL].( 2017-12-27 ). http://www.cde.org.cn/zdyz.do?method=largePage&id=257 .
刘炳林 . 药物临床试验中疗效评价指标及常见评价方法 [J]. 中国新药杂志 , 2016 , 25 ( 18 ): 2074 - 2077 .
国家食品药品监督管理局药品审评中心 . 中药药源性肝损伤临床评价指导原则 [EB/OL].( 2018-6-19 ). http://www.cde.org.cn/zdyz.do?method=largePage&id=21 .
0
浏览量
15
下载量
5
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621